Dehydrozingerone

Name: Dehydrozingerone
Brand: MedChemExpress
SKU: HY-134635
Rating: 4.5 (1 reviews)

Cat. No.: HY-134635 Purity: 99.98%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Dehydrozingerone is a ginger-derived component and cyclin D1 inhibitor that downregulates cyclin D1 expression and induces cell cycle G₁ phase arrest. Dehydrozingerone reduces the proliferative capacity of castration-resistant prostate cancer cells under in vitro conditions. Dehydrozingerone reduces subcutaneous tumor growth by inhibiting cell proliferation and angiogenesis. Dehydrozingerone exerts antibacterial and antifungal activities via its α,β-unsaturated carbonyl conjugated system. Dehydrozingerone can be used in studies related to castration-resistant prostate cancer, bacterial infections, and food spoilage fungal infections.

For research use only. We do not sell to patients.

Dehydrozingerone Chemical Structure

CAS No. : 1080-12-2

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	In-stock	Estimated Time of Arrival: December 31
25 g	In-stock	Estimated Time of Arrival: December 31
50 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Dehydrozingerone:

Dehydrozingerone (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

View All CDK Isoform Specific Products:

View All Isoforms

CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
1A9	ED₅₀	33.9 μM Compound: 4, DZ	Cytotoxicity against human 1A9 cells Cytotoxicity against human 1A9 cells	[PMID: 17591444]
A498	IC₅₀	125 μM Compound: DZG	Antiproliferative activity against human A498 cells after 72 hrs by MTT assay Antiproliferative activity against human A498 cells after 72 hrs by MTT assay	[PMID: 30429098]
A549	ED₅₀	> 52 μM Compound: 4, DZ	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 17591444]
A549	IC₅₀	> 10 μg/mL Compound: 1	Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay Cytotoxicity against human A549 cells after 2 days by sulforhodamine B assay	[PMID: 17067159]
BMDM	IC₅₀	7.5 μM Compound: 2g	Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-based microscopic analysis Inhibition of M-CSF/RANKL-induced osteoclast differentiation in C57BL/6 mouse bone marrow macrophage assessed as reduction in multinucleated TRAP+ cells incubated for 6 days with fresh media replacement on day 3 and measured on day 6 by TRAP staining-based microscopic analysis	[PMID: 31257875]
DU-145	ED₅₀	> 52 μM Compound: 4, DZ	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 17591444]
HCT-116	IC₅₀	34.78 μM Compound: 1; DHZ; Dehydrozingerone	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30108729]
HCT-116	IC₅₀	70 μM Compound: DZG	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 30429098]
HCT-15	IC₅₀	65 μM Compound: DZG	Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT15 cells after 72 hrs by MTT assay	[PMID: 30429098]
HCT-8	ED₅₀	> 52 μM Compound: 4, DZ	Cytotoxicity against human HCT8 cells Cytotoxicity against human HCT8 cells	[PMID: 17591444]
HEK293	IC₅₀	64 μM Compound: DZG	Antiproliferative activity against human HEK293 cells after 72 hrs by MTT assay Antiproliferative activity against human HEK293 cells after 72 hrs by MTT assay	[PMID: 30429098]
K562	GI₅₀	85.33 μM Compound: 2	Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay	[PMID: 27908756]
K562	GI₅₀	92 μM Compound: 2	Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay	[PMID: 27908756]
K562	IC₅₀	68 μM Compound: 4b'	In vitro cell growth inhibitory activity against K562 human chronic myelogenous leukemia cell line In vitro cell growth inhibitory activity against K562 human chronic myelogenous leukemia cell line	10.1016/S0960-894X(97)10147-0
KB	IC₅₀	> 10 μg/mL Compound: 1	Cytotoxicity against human KB cells after 2 days by sulforhodamine B assay Cytotoxicity against human KB cells after 2 days by sulforhodamine B assay	[PMID: 17067159]
KB	IC₅₀	> 10 μg/mL Compound: 1	Cytotoxicity against multidrug-resistant human KB-VCR cells after 2 days by sulforhodamine B assay Cytotoxicity against multidrug-resistant human KB-VCR cells after 2 days by sulforhodamine B assay	[PMID: 17067159]
LNCaP	ED₅₀	51 μM Compound: 4, DZ	Cytotoxicity against human LN-Cap cells Cytotoxicity against human LN-Cap cells	[PMID: 17591444]
M14	IC₅₀	550 μM Compound: DZG	Antiproliferative activity against human M14 cells after 72 hrs by MTT assay Antiproliferative activity against human M14 cells after 72 hrs by MTT assay	[PMID: 30429098]
MCF7	IC₅₀	31 μM Compound: DZG	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30429098]
MCF7	IC₅₀	54.65 μM Compound: 1; DHZ; Dehydrozingerone	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30108729]
MDA-MB-231	IC₅₀	86 μM Compound: DZG	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 30429098]
NCI-H322M	IC₅₀	96 μM Compound: DZG	Antiproliferative activity against human NCI-H322M cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H322M cells after 72 hrs by MTT assay	[PMID: 30429098]
NCI-H460	GI₅₀	64.75 μM Compound: 2	Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27908756]
OVCAR-4	IC₅₀	139 μM Compound: DZG	Antiproliferative activity against human OVCAR4 cells after 72 hrs by MTT assay Antiproliferative activity against human OVCAR4 cells after 72 hrs by MTT assay	[PMID: 30429098]
PC-3	ED₅₀	> 52 μM Compound: 4, DZ	Cytotoxicity against human PC3 cells Cytotoxicity against human PC3 cells	[PMID: 17591444]
PC-3	IC₅₀	43.21 μM Compound: 1; DHZ; Dehydrozingerone	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 30108729]
PC-3	IC₅₀	68 μM Compound: DZG	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 30429098]
Raji	IC₅₀	95 molar ratio Compound: DZG; Dehydrozingerone	Cytotoxicity against human Raji cells expressing EBV-EA assessed as inhibition of TPA-induced EBV-EA activation after 48 hrs by trypan blue staining based immunofluorescence method relative to TPA Cytotoxicity against human Raji cells expressing EBV-EA assessed as inhibition of TPA-induced EBV-EA activation after 48 hrs by trypan blue staining based immunofluorescence method relative to TPA	[PMID: 26796952]
SNB-19	IC₅₀	138 μM Compound: DZG	Antiproliferative activity against human SNB19 cells after 72 hrs by MTT assay Antiproliferative activity against human SNB19 cells after 72 hrs by MTT assay	[PMID: 30429098]
ZR-75-1	ED₅₀	> 52 μM Compound: 4, DZ	Cytotoxicity against human ZR751 cells Cytotoxicity against human ZR751 cells	[PMID: 17591444]

In Vitro

Dehydrozingerone (0-200 μM; 48 h) inhibits the proliferation of rat castration-resistant prostate cancer PLS10 cells in vitro with an IC₅₀ of 153.13 μM^[1].
Dehydrozingerone (0-200 μM; 48 h) induces G1 phase cell cycle arrest and downregulates cyclin D1 expression in rat castration-resistant prostate cancer PLS10 cells at concentrations of 150 and 200 μM for 48 h^[1].
Dehydrozingerone (1 mg) exhibits strong antifungal activity against Aspergillus niger, Aspergillus ochraceus, Aspergillus flavus, and Penicillium sp., with the largest inhibition zones measured at 31.0 ± 1.0 mm and 31.5 ± 3.5 mm for Aspergillus niger and Penicillium sp., respectively^[2].
Dehydrozingerone (1041 μM; 5 to 7 d) exerts potent antifungal activity against multiple food spoilage fungal pathogens, with the largest inhibition zones observed against Penicillium chrysogenum (29.5 mm) and Aspergillus ochraceus (30.5 mm)^[3].
Dehydrozingerone (260-1041 μM; up to 10 d) inhibits growth and sporulation of Aspergillus ochraceus in a concentration- and time-dependent manner, with complete sporulation prevention at 781 μM when applied within 2 days of inoculation and 100% growth inhibition at 1041 μM after 5 d of incubation^[3].
Dehydrozingerone (260-1041 μM) reduces the levels of key biomolecules (DNA, RNA, protein, total sugars) and biomass in Aspergillus ochraceus, with the most pronounced effects on biomolecule levels observed at 260 μM and the highest growth inhibition at 1041 μM^[3].
Dehydrozingerone (520-1041 μM) disrupts the cellular morphology of Aspergillus ochraceus, causing hyphal collapse, conidial shrinkage, and mycelial damage, indicating interference with cell wall synthesis and fungal morphogenesis^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	rat castration-resistant prostate cancer PLS10 cells
Concentration:	0, 25, 50, 100, 150, 200 μM
Incubation Time:	48 h
Result:	Significantly inhibited cell proliferation in a dose-dependent manner. Reached an IC₅₀ value of 153.13 μM.

Cell Cycle Analysis^[1]

Cell Line:	rat castration-resistant prostate cancer PLS10 cells
Concentration:	0, 50, 100, 150, 200 μM
Incubation Time:	48 h
Result:	Increased the G1 phase cell population from 35.93% (control) to 42.88% and decreased the G2/M phase population from 48.18% (control) to 39.25% at 150 μM. Increased the G1 phase cell population to 52.95% and decreased the G2/M phase population to 31.00% at 200 μM. Significantly reduced cyclin D1 expression at 150 and 200 μM.

In Vivo

Dehydrozingerone (30 mg/kg; i.p.; twice weekly; 5 weeks) significantly inhibits prostate cancer xenograft growth (reducing final tumor volume to 24 cm³, p < 0.05) via suppression of tumor cell proliferation and angiogenesis, with no observed toxicity in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c-nu/nu (5-week-old male, subcutaneous xenograft model)^[1]
Dosage:	30 mg/kg
Administration:	i.p.; twice weekly; 5 weeks
Result:	Reduced final tumor volume from 96 cm³ (control) to 24 cm³. Decreased Ki67-labeling index from 63 (control) to 59. Increased percentage of TUNEL-positive apoptotic cells from 7% (control) to 10%. Reduced percentage of CD31-positive vessel area significantly.

Molecular Weight

192.21

Formula

C₁₁H₁₂O₃

CAS No.

1080-12-2

Appearance

Solid

Color

Off-white to light yellow

SMILES

CC(/C=C/C1=CC=C(O)C(OC)=C1)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

RT, stored under nitrogen

In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (520.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.2026 mL	26.0132 mL	52.0264 mL
5 mM	1.0405 mL	5.2026 mL	10.4053 mL
10 mM	0.5203 mL	2.6013 mL	5.2026 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (26.01 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 5 mg/mL (26.01 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 5 mg/mL (26.01 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.98%

Select Batch:

Data Sheet (278 KB) SDS (393 KB)

COA (246 KB) HNMR (120 KB) RP-HPLC (223 KB)

Handling Instructions (2659 KB)

References

[1]. Mapoung S, et al. Dehydrozingerone, a Curcumin Analog, as a Potential Anti-Prostate Cancer Inhibitor In Vitro and In Vivo. Molecules. 2020;25(12):2737. Published 2020 Jun 12. [Content Brief]

[2]. Kubra IR, et al. Structure-function activity of dehydrozingerone and its derivatives as antioxidant and antimicrobial compounds. J Food Sci Technol. 2014;51(2):245-255. [Content Brief]

[3]. Kubra IR, et al. In vitro antifungal activity of dehydrozingerone and its fungitoxic properties. J Food Sci. 2013;78(1):M64-M69. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.2026 mL	26.0132 mL	52.0264 mL	130.0661 mL
	5 mM	1.0405 mL	5.2026 mL	10.4053 mL	26.0132 mL
	10 mM	0.5203 mL	2.6013 mL	5.2026 mL	13.0066 mL
	15 mM	0.3468 mL	1.7342 mL	3.4684 mL	8.6711 mL
	20 mM	0.2601 mL	1.3007 mL	2.6013 mL	6.5033 mL
	25 mM	0.2081 mL	1.0405 mL	2.0811 mL	5.2026 mL
	30 mM	0.1734 mL	0.8671 mL	1.7342 mL	4.3355 mL
	40 mM	0.1301 mL	0.6503 mL	1.3007 mL	3.2517 mL
	50 mM	0.1041 mL	0.5203 mL	1.0405 mL	2.6013 mL
	60 mM	0.0867 mL	0.4336 mL	0.8671 mL	2.1678 mL
	80 mM	0.0650 mL	0.3252 mL	0.6503 mL	1.6258 mL
	100 mM	0.0520 mL	0.2601 mL	0.5203 mL	1.3007 mL